This FREE webcast series gives you direct access to companies that have the potential to be the next big thing – it’s an ideal platform for you to identify fast growing, high value opportunities.
Wednesday, 4th November 12pm (AEDT)
Each session features a selection of CEOs who provide a succinct overview of big things their companies are doing, followed by an interactive Q&A.
This week we are joined by:
- (ASX: RFF) Rural Funds Group – James Powell, General Manager
- (AZT) Azure Health Technology – Glenn Tong, Managing Director
- (ASX: PTX) Prescient Therapeutics – Steven Yatomi-Clarke, Chief Executive Officer
General Manager - Rural Funds Group (ASX: RFF)
Rural Funds Group (ASX: RFF) is a real estate investment trust (REIT) which owns a diversified portfolio of high quality Australian agricultural assets that are leased to experienced agricultural operators. RFF targets distribution growth of 4% per annum by owning and improving farms that are leased to good counterparties.
Managing Director - Azure Health Technology (AZT)
Azure Health Technology Limited (AZT) is an Australian public unlisted biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential. AZT owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.
Chief Executive Officer - Prescient Therapeutics (ASX: PTX)
Prescient Therapeutics (ASX:PTX) are focused on developing novel, personalised therapies for a range of cancers. Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches which seek to improve patient outcomes, whilst also providing new tools for clinicians in combating cancer. Prescient has a broad pipeline of personalised cancer treatments, comprising CAR-T and targeted therapies, and has licensed technologies from and in collaboration with world-leading cancer centers in the US and Australia.